» Articles » PMID: 20643259

Usefulness of the Right Ventricular Systolic to Diastolic Duration Ratio to Predict Functional Capacity and Survival in Children with Pulmonary Arterial Hypertension

Overview
Journal Am J Cardiol
Date 2010 Jul 21
PMID 20643259
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

The objective of this study was to investigate the systolic to diastolic duration ratio (S:D ratio) in children with pulmonary arterial hypertension (PAH) and its association with right ventricular (RV) performance, hemodynamics, 6-minute walk test, clinical outcomes, and survival. We reviewed 503 serial echocardiograms in 47 children with PAH (mean pulmonary artery pressure >or=25 mm Hg) and compared the S:D ratio, assessed from Doppler flow of tricuspid valve regurgitation, to that in 47 age-matched controls. We reviewed echocardiograms, catheterization data, 6-minute walk tests, clinical data, lung transplantation, and death and used univariate linear regression models with a maximum likelihood algorithm for parameter estimation to investigate associations between S:D ratio and RV function, hemodynamics, functional capacity, and clinical outcomes. The S:D ratio was significantly higher in patients than in controls (1.38 +/- 0.61 vs 0.72 +/- 0.16, p <0.001). A higher S:D ratio was associated with worse echocardiographic RV fractional area of change, worse catheterization hemodynamics, shorter 6-minute walk distance, and worse clinical outcomes independent of pulmonary resistance or pressures. An increase of 0.1 in the S:D ratio was associated with a 13% increase in yearly risk for lung transplantation or death (hazard ratio 1.13, p <0.001). An S:D ratio 1.00 to 1.40 was associated with a moderate risk and an S:D ratio >1.40 was associated with a high risk of a negative outcome. In conclusion, in children with PAH, an increased S:D ratio is temporally associated with worse RV function, hemodynamics, exercise capability, clinical status, and survival.

Citing Articles

Digital measurement of mobility in pulmonary arterial hypertension: A structured review of an emerging area.

Robertson E, Naghavi N, Wipperman M, Tuckwell K, Effendi M, Alaj R Digit Health. 2024; 10:20552076241277174.

PMID: 39291158 PMC: 11406665. DOI: 10.1177/20552076241277174.


Biventricular responses to exercise and their relation to cardiorespiratory fitness in pediatric pulmonary hypertension.

Pieles G, Dorobantu D, Caterini J, Cifra B, Reyes J, Roldan Ramos S Am J Physiol Heart Circ Physiol. 2024; 327(4):H749-H764.

PMID: 39058433 PMC: 11482283. DOI: 10.1152/ajpheart.00096.2024.


Pulmonary hypertension.

Mocumbi A, Humbert M, Saxena A, Jing Z, Sliwa K, Thienemann F Nat Rev Dis Primers. 2024; 10(1):1.

PMID: 38177157 DOI: 10.1038/s41572-023-00486-7.


Myocardial strain-curve deformation patterns after Fontan operation.

Schafer M, Mitchell M, Frank B, Barker A, Stone M, Jaggers J Sci Rep. 2023; 13(1):11912.

PMID: 37488167 PMC: 10366156. DOI: 10.1038/s41598-023-39226-y.


Safety and Efficacy of Sildenafil for Group 2 Pulmonary Hypertension in Left Heart Failure.

Desai K, Di Lorenzo M, Zuckerman W, Emeruwa E, Krishnan U Children (Basel). 2023; 10(2).

PMID: 36832399 PMC: 9955063. DOI: 10.3390/children10020270.